CAR T-Cell Therapy Highlights From the 2019 ASH Annual Meeting

Michael R. Bishop, MD

Disclosures

January 02, 2020

At the 2019 American Society of Hematology annual meeting, a number of presentations covered chimeric antigen receptor (CAR) T cells. CAR T-cell therapies have demonstrated high response rates across hematologic cancers. Dr Michael Bishop highlights salient therapies that are likely to garner approvals in the near future.

In a study of KTE-X19 in patients with refractory/relapsed mantle cell lymphoma, updated results from ZUMA-2 showed that in 68 patients, the overall response rate (ORR) was 93%, and the complete response was 67%. With these impressive findings, Dr Bishop suggests that KTE-X19 is poised for FDA approval in mantle cell lymphoma.

Lisocabtagene maraleucel (liso-cel) targets CD19, but it is uniquely manufactured in a fixed ratio of CD4+ and CD8+ T cells. Liso-cel produced impressive responses in patients with large B-cell lymphomas, such as DLBCL (studied in TRANSCEND NHL00).

Finally, in CARTITUDE-1, JNJ-4528 was studied in patients with multiple myeloma. This study created a buzz because it showed 100% ORR, of which 69% were stringent complete responses.

The unique toxicities of CAR T-cell therapies, such as cytokine release syndrome, are being better managed with tocilizumab and corticosteroids.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....